Tag: newswire

In this 2025 ingredient transparency update, Emma highlights growing public interest in methane-producing gut bacteria, microbiome imbalance, and non-clinical digestive support. The release explores how plant-based formulations may help support intestinal motility, microbial balance, and daily bowel regularity without relying on probiotics or synthetic cleanses.

DRML Miner introduces automated XRP rewards with AI-optimized contract options

Clean-label hydration meets real-world functionality in NativePath’s new stick pack assortment featuring natural flavors, third-party tested ingredients, and a complete hydration matrix designed for daily wellness.

Clinicians’ Choice Fat Burner for Women, PhenQ: Clinically Endorsed by 800 Healthcare Professionals Launched Over the Counter in the USA and Worldwide.

NativePath’s Clean-Label Creatine Powder Combines L-Leucine, L-Carnitine, and Creatine Monohydrate for Daily Muscle and Energy Support Without Resistance Training

Toronto, Canada, July 08, 2025 (GLOBE NEWSWIRE) -- Kaleo AI announced the official launch of its groundbreaking real-time translation platform designed specifically for churches, enabling congregations to instantly translate their services into more than 150 languages and dialects. With this solution, churches can finally reach diverse communities with the gospel, removing language as a barrier to worship and discipleship.

Transforming Healthcare Ltd Unveils the Healthcare Convergence Framework® AI/Robotics Self-Assessment Scorecard

SANTA BARBARA, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- Public safety advocacy group The Dawn Project has called on legislators to take action to ban Tesla’s Full Self-Driving software from public roads over the litany of critical safety defects uncovered by the group’s safety tests of the software.

What you need to know:

WESTON, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today announced its entry into a warrant inducement agreement with a single institutional investor of the Company. Terms of the warrant inducement agreement include the immediate exercise of Series A-2 Warrants to purchase up to 957,200 shares of common stock (the “Series A-2 Warrants”) and Series A-3 Warrants to purchase up to 2,105,265 shares of common stock (the “Series A-3 Warrants,” and together with the Series A-2 Warrants, the “Existing Warrants”) at a reduced exercise price of $0.67. Gross cash proceeds were approximately $2.0 million before deducting financial advisor fees and other transaction expenses. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.